Experienced in Primitive Neuroectodermal Tumor (PNET)

Dr. Amy N. Sanford

Hematology Oncology | Hematology | Oncology
Avera Mckennan
1325 S Cliff Ave, 
Sioux Falls, SD 
Accepting New Patients
Offers Telehealth
16 Years of Experience
Experienced in Primitive Neuroectodermal Tumor (PNET)
Avera Mckennan
1325 S Cliff Ave, 
Sioux Falls, SD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Amy Sanford is a Hematologist Oncology specialist and a Hematologist in Sioux Falls, South Dakota. Dr. Sanford has been practicing medicine for over 16 years and is rated as an Experienced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration. Dr. Sanford is currently accepting new patients.

Her clinical research consists of co-authoring 4 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2009
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IA
Hospital Affiliations
Avera St Mary's Hospital
Sioux Center Health
Avera Queen Of Peace
Avera Mckennan Hospital & University Health Center
Spencer Municipal Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avera Health
  • HMO
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Sanford
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 9 Less Insurance Carriers -

Locations

AVERA MCKENNAN
1325 S Cliff Ave, Sioux Falls, SD 57105
Other Locations
AVERA MCKENNAN
400 22nd Ave, Brookings, SD 57006

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Phase I Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Low-Expressing (IHC 1+/2+) Breast Cancer
Phase I Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Low-Expressing (IHC 1+/2+) Breast Cancer
Enrollment Status: Terminated
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drug: ETBX-021
Study Phase: Phase 1
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Biological
Study Drugs: Nab-Paclitaxel, Cisplatin, Carboplatin, Cetuximab
Study Phase: Phase 2
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): The APA Trial.
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): The APA Trial.
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug, Radiation, Biological
Study Drugs: Nab-Paclitaxel, Cisplatin, Cetuximab
Study Phase: Phase 2
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
Enrollment Status: Withdrawn
Publish Date: November 18, 2023
Intervention Type: Drug
Study Phase: Phase 1
View 4 Less Clinical Trials

4 Total Publications

Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Journal: Nature medicine
Published: August 07, 2024
Similar Doctors
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Heidi A. Mckean
Hematology Oncology | Hematology | Oncology
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Heidi A. Mckean
Hematology Oncology | Hematology | Oncology

Avera Mckennan

1325 S Cliff Ave, 
Sioux Falls, SD 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Heidi Mckean is a Hematologist Oncology specialist and a Hematologist in Sioux Falls, South Dakota. Dr. Mckean is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Familial Pancreatic Cancer, Lung Cancer, Pleuropulmonary Blastoma, and Familial Colorectal Cancer. Dr. Mckean is currently accepting new patients.

Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Benjamin Solomon
Hematology | Oncology
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Benjamin Solomon
Hematology | Oncology

Avera Mckennan

1000 E 23rd St, Suite 230, 
Sioux Falls, SD 
 (0.2 miles away)
605-322-6900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Benjamin Solomon is a Hematologist and an Oncologist in Sioux Falls, South Dakota. Dr. Solomon is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Lung Cancer, Neuroendocrine Tumor, Colorectal Cancer, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration.

Experienced in Primitive Neuroectodermal Tumor (PNET)
Dr. Mark R. Huber
Hematology Oncology | Hematology | Oncology
Experienced in Primitive Neuroectodermal Tumor (PNET)
Dr. Mark R. Huber
Hematology Oncology | Hematology | Oncology

Avera Mckennan

1325 S Cliff Ave, 
Sioux Falls, SD 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Huber is a Hematologist Oncology specialist and a Hematologist in Sioux Falls, South Dakota. Dr. Huber is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Lung Cancer, Large-Cell Immunoblastic Lymphoma, Familial Wilms Tumor 2, Chromophobe Renal Cell Carcinoma, and Bone Marrow Aspiration. Dr. Huber is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sanford's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 27 Advanced Conditions
    View All 128 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile